This variability may be attributed to the lack of a universally acknowledged, standardized protocol in reporting HER2 expression in CRC, resulting in studies using different antibodies, different scoring systems for the interpretation of results, or having different sample sizes [8]. The gene discussed is ERBB2; the disease is colorectal carcinoma.